Chief Operating Officer and Executive Vice President, Product Development · Nurix Therapeutics, Inc. (NRIX)

Stefani Wolff

FY2021 is the first fiscal year CompBrief holds for Stefani Wolff as a named executive officer of Nurix Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$7,148,424

Salary $164,576Stock awards $0Bonus $150,000

1st of 5 named executive officers at Nurix Therapeutics by FY2021 total.

5 named officers on file for Nurix Therapeutics, FY2021

Stefani Wolff’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • NRIX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Nurix Therapeutics’s whole pay program stands against its peers

  • Nurix Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NRIX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 25, 2022 (DEF 14A).

Free

Get Stefani Wolff’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stefani Wolff compensation by year

Nurix Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Nurix Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$164,576
Bonus$150,000
Stock awards$0
Option awards$6,761,172
Non-equity incentive$67,766
Pension and deferred compensation$0
All other$4,910
Total$7,148,424

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nurix Therapeutics, Inc. DEF 14A filed March 25, 2022, accession 0001193125-22-084520, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Nurix Therapeutics, Inc. filed document, accession 0001193125-22-084520. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option443,865—$23.23

Per the Outstanding Equity Awards at Fiscal Year-End table in Nurix Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Nurix Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Stefani Wolff · this pageChief Operating Officer and Executive Vice President, Product Development$7,148,424
Arthur SandsPresident, Chief Executive Officer and Director$4,791,466
Gwenn HansenChief Scientific Officer$2,303,328
Hans van HouteChief Financial Officer$1,659,957
Christine RingGeneral Counsel and Secretary$1,648,895

The full Nurix Therapeutics compensation record

free company brief

This page is one person within Nurix Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Nurix Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nurix Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stefani Wolff's compensation dossier · One-time report. No refunds.